Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Poliovirus type 2 capsid protein VP1-VP4 complex consists of four distinct polypeptides—VP1, VP2, VP3, and VP4—that assemble into an icosahedral shell encapsulating the single-stranded RNA genome of poliovirus. Each mature virion contains 60 copies each of these four subunits arranged symmetrically to form the protective outer layer known as the *capsid*. The outer surface primarily comprises VP1–VP3; their arrangement creates characteristic "canyons" involved in binding to host cell receptors such as PVR/CD155. During virus assembly inside infected cells, precursor forms like VP0 are cleaved into mature components including VP4. This structure protects viral genetic material from environmental degradation and mediates initial interactions with susceptible human cells during infection
No direct mechanism of action for drugs targeting this entire complex. Some experimental antivirals may aim to destabilize the capsid or block its assembly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus type 2 capsid protein VP1-VP4 complex.